Volume 144 Issue 22 | Blood | American Society of Hematology
Blood | 144 | 22 | November 2024
Related Articles
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort
Key PointsEmicizumab provides effective outpatient hemostatic prophylaxis for AHA.Rituximab with concurrent emicizumab seems to be safe and promising for A
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC? – Oncology Nurse Advisor
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A Quick Start Guide to Cancer Data Science for Clinical Oncology | CBIIT
Whether you are in the data science field, interested in developing computational solutions for clinical oncology, or a clinical researcher, we’ve curated a list of…
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Research Aims to Expand RAS Inhibitor Options in Pancreatic Cancer
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study
Key PointsPatients with cancer are at high risk of clinically relevant bleeding, regardless of anticoagulation use.The occurrence of clinically relevant bl
A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML
Key Points. CD70 targeted CAR-T cells secreting a CD33 T-cell engaging antibody molecule eradicate CD33 or CD70 deficient AML
